EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome
November 18, 2024 08:00 ET
|
EnteroBiotix
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome 122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase...
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome
November 18, 2024 03:00 ET
|
EnteroBiotix
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome 122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase...
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues
November 12, 2024 08:10 ET
|
NeurAxis, Inc.
CARMEL, Ind., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...
NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market
November 04, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Nov. 04, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain
October 30, 2024 08:19 ET
|
Biomerica, Inc.
Patients experiencing bloating and gastrointestinal discomfort can now order inFoods® IBS directly from www.infoodsIBS.com without needing to visit a doctor’s officeWith a simple, at-home finger-prick...
NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation
October 22, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
September 19, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Sept. 19, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...
NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024
August 27, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024
August 13, 2024 09:00 ET
|
NeurAxis, Inc.
CARMEL, Ind., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
Global Gut Microbiota Markets, Insights and Forecasts to 2031 - Key Players Danone, IFF, Ferring, and Nestle Focusing on R&D and Strategic Partnerships
July 12, 2024 05:35 ET
|
Research and Markets
Dublin, July 12, 2024 (GLOBE NEWSWIRE) -- The "Gut Microbiota Market, By Product, By Application, By Disease Type, By End Users, By Distribution Channel: By Region - Market Size, Industry Dynamics,...